Recent developments include strong Q2 revenue reporting, strategic acquisitions, and partnerships to expand the company's wellness ecosystem and telemedicine platform.

• MedWellAI reported strong Q2 revenues of $548,315 and provided guidance for full year 2025 exceeding $2,200,000 [N1].
• The company executed a letter of intent to create America's first vertically integrated regenerative wellness ecosystem [N1].
• MedWellAI joined Trump Mobile in engaging BrighterMD to develop an AI-enhanced healthcare telemedicine platform focused on the $24.46 billion corporate wellness market [N1].

MedWellAI's platform addresses a niche in the compounded pharmaceutical market by connecting healthcare providers with multiple 503B pharmacies, offering a broad product range and automated fulfillment. Strategic acquisitions and partnerships, such as the acquisition of Healthy Lifestyle USA LLC and collaboration with BrighterMD for AI-enhanced telemedicine, position the company to capitalize on the growing wellness and corporate wellness markets. The company's ability to generate commissions and rental income demonstrates initial commercial traction. The use of AI and emerging technologies could enhance operational efficiencies and product offerings if managed effectively [S1][N1].

MedWellAI faces significant risks including regulatory changes by the FDA that could restrict the supply of key compounded pharmaceutical products, impacting its core business. The company has a history of losses, minimal revenue, and liquidity constraints with a current ratio of 0.01, indicating potential financial distress. Dependence on a small management team and the CEO increases operational risk. The use of AI technologies introduces risks related to compliance, cybersecurity, and competitive disadvantage. Additional capital requirements may lead to dilution or restrictive financing terms. The competitive and regulatory environment for compounded pharmaceuticals is complex and could adversely affect business operations [S1].

MedWellAI's moat is based on its proprietary fully automated e-commerce platform that integrates multiple FDA-registered 503B pharmacies, enabling efficient, compliant, and cost-effective distribution of compounded pharmaceutical products. The platform's turnkey solution for procurement agents and resellers, combined with personalized pricing and direct payment deposits, creates operational efficiencies and barriers to entry. However, the company operates in a highly regulated and competitive environment with narrow legal pathways for compounding, which may limit scalability and create ongoing compliance challenges. The company's early-stage status and limited financial resources also constrain its competitive positioning [S1].

• Regulatory Risk: FDA regulatory changes proposed in 2026 could exclude key GLP-1 drugs from the 503B Bulks List, limiting supply of compounded products and adversely affecting the business.
• Financial and Liquidity Risk: The company reported a net loss and has liquidity constraints with a current ratio of 0.01 as of June 30, 2026, indicating potential challenges in meeting short-term obligations.
• Operational Risk: Dependence on a small team and the CEO, along with the complexity of managing AI technologies, creates operational vulnerabilities.
• Compliance and Quality Risk: 503B pharmacies face inspection and compliance challenges that could result in product recalls, warnings, or supply disruptions impacting MedWellAI's offerings.
• Capital Raising Risk: Future capital needs may lead to dilution of existing stockholders or restrictive covenants that could limit operational flexibility.
• Technology Risk: Use of AI and emerging technologies carries risks of deficiencies, regulatory compliance challenges, cybersecurity incidents, and competitive disadvantages.

• MedWellAI, Inc. is a publicly traded company (OTCQB: MWAI) based in Clearwater, Florida focused on earning commissions through a fully automated e-commerce platform connecting in-office buyers with multiple FDA-registered 503B pharmacies offering GLP-1 weight management therapies, peptides, and other compounds [S1].
• The company markets a turnkey, custom solution for qualified procurement agents and resellers to market in-office use products, enabling marketing to licensed healthcare providers, wellness spas, and telemedicine companies in an automated, cost-effective, compliant manner without infrastructure investment [S1].
• Key features of the platform include access to multiple 503B outsourcing facilities, over 100 products, personalized pricing, direct payment deposits, custom domain options, and onboarding support [S1].
• The platform manages seamless ordering, fulfillment, and shipping directly by the 503B facilities [S1].
• MedWellAI formed three wholly-owned subsidiaries in July 2024: MedWell Direct, LLC, MedWell Facilities, LLC, and MedWell USA, LLC [S1].
• In August 2024, MedWell Direct acquired 51% membership interest in Healthy Lifestyle USA LLC [S1].
• The company has undergone several name changes and corporate restructuring since incorporation in 2011, most recently changing its name to MedWellAI, Inc. in June 2025 [S1].
• MedWellAI reported revenues of $527,857 for the fiscal year ended June 30, 2026, primarily from commissions, with rental income of $90,000 and no revenue from online sales due to regulatory hurdles [S1].
• The company reported a net loss of $1,589,465 for the fiscal year ended June 30, 2026 [S1].
• Cash and cash equivalents were $57,815 as of June 30, 2024, with current assets of $111,877 and current liabilities of $7,959,140 as of June 30, 2026, resulting in a current ratio of 0.01 and cash ratio of 0.01, indicating liquidity constraints [S1].
• MedWellAI discontinued its digital asset mining operations as of June 7, 2024, recognizing a gain on settlement of payables and reporting mining operations as discontinued [S1].
• The company has five full-time employees including the sole officer and director, Steve Rubakh, who devotes 100% of his time to operations [S1].
• MedWellAI has filed amendments to its preferred stock structure, including increasing authorized shares of Series B Convertible Preferred Stock and amending Series C Convertible Preferred Stock terms [S1].
• The company faces risks including its early-stage status with minimal revenue and history of losses, regulatory risks related to FDA changes affecting compounded pharmaceuticals supply, and operational risks related to AI technology use [S1].
• Regulatory changes proposed by the FDA in April 2026 could exclude certain GLP-1 drugs from the 503B Bulks List, potentially limiting supply of products distributed by MedWellAI [S1].
• 503B outsourcing facilities face inspection and compliance challenges that could impact product availability and quality, affecting MedWellAI's business [S1].
• MedWellAI uses AI and emerging technologies in operations, which present risks including potential deficiencies, regulatory compliance challenges, cybersecurity risks, and competitive disadvantages [S1].
• The company may require additional capital to fund operations and expansion, with potential dilution or restrictive covenants affecting stockholders [S1].
• MedWellAI is dependent on its CEO, Steve Rubakh, and has limited employee benefits currently [S1].
• Recent news includes MedWellAI reporting strong Q2 revenues of $548,315 and providing guidance for full year 2025 exceeding $2,200,000 [N1].
• MedWellAI executed a letter of intent to create America's first vertically integrated regenerative wellness ecosystem [N1].
• MedWellAI joined Trump Mobile in engaging BrighterMD to develop an AI-enhanced healthcare telemedicine platform focused on the $24.46 billion corporate wellness market [N1].